Ocular Therapeutix, Inc.
NASDAQ:OCULBiotechnology
-$0.11 today
- Market cap
- $1.31B
- Beta
- 0.90
- P/E (TTM)
- -7.3
- EPS (TTM)
- -$1.30
Volume 3.67M
Average 3.00M
OCUL Financing Cash Flow
Net cash exchanged with lenders and shareholders through borrowing, repayments, buybacks, and dividends.
Ocular Therapeutix, Inc.NASDAQ: OCUL
Financing Cash Flow · Q1 FY2026 · quarter ended Mar 2026
Financing cash flow dips below year-ago levels
Q1 FY2026 financing cash flow of $294K fell 93.0% year over year, behind the +3601.6% change in trailing-twelve-month financing cash flow. Sequentially, it fell 99.9% from the prior quarter. Over 3 fiscal years it compounded at +628.3% a year.
Context
- Financing cash flow amounted to 1083.9% of revenue in FY2025, up 562.7 pp from a year earlier.
- Financing cash flow increased in 3 of the last 3 fiscal years.
- FY2025 was the highest annual figure in the 4 fiscal years shown.
What to watch
Whether quarterly growth recovers from -93.0% toward the trailing-twelve-month pace of +3601.6%.
Sources:Cash FlowText generated from reported figures; not investment advice.
Financing Cash Flow history
USD · from the cash flow
- Latest · FY2025
- 561.72M USD
- Year-over-year change
- +69.1%
- 4-year CAGR
- +274.7%
| Period | Period end | Financing Cash Flow | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 561.72M | +69.1% |
| FY2024 | 2024-12-31 | 332.11M | +95.6% |
| FY2023 | 2023-12-31 | 169.83M | +11580.1% |
| FY2022 | 2022-12-31 | 1.45M | -49.0% |
| FY2021 | 2021-12-31 | 2.85M | — |
Financing Cash Flow vs competitors
How OCUL compares with its peers on the latest reported figures
- Peers report in different currencies, so financing cash flow is compared through growth and share of revenue rather than absolute size.
- Its year-over-year change of +3601.6% is the 2nd highest of 10, against a peer median of -16.0%.
- Financing cash flow amounts to 1072.0% of revenue for OCUL, versus a peer median of 606.5%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Mar 2026 | $557.83M USD | +3601.6% | +628.3% | 1072.0% | |
| LTM Sep 2026 | $187.21M USD | +12713.7% | +354.8% | — | |
| LTM Mar 2026 | $171.98M USD | +5.5% | — | 2258.5% | |
SGPSpyGlass Pharma, Inc. Common Stock | FY2025 | $124.59M USD | — | — | — |
| LTM Jun 2026 | $116.25M USD | -52.9% | +40.6% | 2.2% | |
| LTM Mar 2026 | CHF 105.86M CHF | -32.9% | +370.6% | 21003.4% | |
| LTM Mar 2026 | $53.56M USD | -16.0% | -33.7% | 1199.5% | |
| LTM Mar 2026 | $47.24M USD | +93.8% | -8.9% | 14179.4% | |
| LTM Mar 2026 | $36.17M USD | +23.2% | — | 13.5% | |
| LTM Jun 2026 | $24.41M USD | -67.0% | +23.9% | 4.0% | |
| LTM Apr 2026 | $5.3M USD | -836.1% | — | 1.8% | |
| Peer median (excluding OCUL) | — | -16.0% | +32.2% | 606.5% | |
Competitors are the stored peer set for OCUL. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Cash Flow Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Net Income | (6.55M) | (71.04M) | (80.74M) | (193.51M) | (265.94M) |
| Depreciation & Amortization | 2.42M | 2.11M | 2.98M | 3.79M | 4.32M |
| Deferred Income Tax | 0 | 0 | 0 | 0 | 0 |
| Stock-Based Compensation | 14.98M | 16.96M | 17.83M | 33.11M | 43.18M |
| Change in Working Capital | (2.9M) | 1.35M | (7.41M) | (10.23M) | 7.71M |
| Accounts Receivables | (8.88M) | (190K) | (4.85M) | (6.21M) | 1.74M |
| Inventory | (49K) | (724K) | (331K) | (735K) | (524K) |
| Accounts Payables | 1.8M | (621K) | 583K | (318K) | (887K) |
| Other Working Capital | 4.24M | 2.88M | (2.81M) | (2.97M) | 7.38M |
| Other Non-Cash Items | (73.49M) | (8.99M) | (2.9M) | 32.16M | 5.84M |
| Operating Cash Flow | (65.55M) | (59.6M) | (70.23M) | (134.68M) | (204.88M) |
| Capital Expenditures | (1.19M) | (3.72M) | (6.09M) | (1.29M) | (12.01M) |
| Acquisitions (Net) | 0 | 0 | 0 | 0 | 0 |
| Purchases of Investments | 0 | 0 | 0 | 0 | 0 |
| Sales of Investments | 0 | 0 | 0 | 0 | 0 |
| Other Investing Activities | 0 | 0 | 0 | 0 | 130K |
| Investing Cash Flow | (1.19M) | (3.72M) | (6.09M) | (1.29M) | (11.88M) |
| Debt Repayment | (445K) | 0 | 56.35M | 316.35M | 0 |
| Common Stock Issued | 985K | 940K | 118.11M | 316.35M | 561.72M |
| Common Stock Repurchased | 0 | 0 | 0 | 0 | 0 |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 |
| Other Financing Activities | 2.31M | 514K | (4.63M) | (300.6M) | 0 |
| Financing Cash Flow | 2.85M | 1.45M | 169.83M | 332.11M | 561.72M |
| Effect of Forex Changes | 0 | 0 | 0 | 0 | 0 |
| Net Change in Cash | (63.89M) | (61.86M) | 93.51M | 196.15M | 344.96M |
| Free Cash Flow | (66.74M) | (63.32M) | (76.32M) | (135.97M) | (216.89M) |
Ocular Therapeutix, Inc.
NASDAQ:OCUL
Intrinsic Alpha fair value
Locked
Current Price
$5.94
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.